Women's Health & GLP-1s
The stories at the intersection of these medications and our actual lives — the hormones, the energy, the cycles, the family planning. Most GLP-1 coverage is written as if the patient is a 45-year-old man named Dave. This page is for the rest of us.
The Tirzepatide + NAD+ Combination Quietly Becoming the Mom Standard
Personalized formulas pairing tirzepatide with NAD+ are spreading fast through women's-health telehealth — targeting the two things moms list first: weight that won't move and energy that's already gone.
Read the story
The Perimenopause Story Nobody Is Telling Loud Enough
GLP-1s are emerging as one of the most useful new tools for women in their forties and fifties — the window where insulin resistance climbs, sleep tanks, and what used to work stops working.
Explore the research
Why So Many Women With PCOS Are Asking About GLP-1s
GLP-1s' effect on insulin and androgens is one of the most-watched stories in the class, with early research pointing to improved cycles and metabolic markers. Promising — and still off-label.
Explore the research
Pregnancy Planning on a GLP-1: The Timeline Conversation
If another baby is on the horizon — or even a "maybe" — clinicians generally advise a planned pause well before conception. Compounding's slow taper fits real timelines better than fixed-dose pens.
See the checklist
The Muscle Problem: Why Protein Is the Other Half of the Prescription
A meaningful share of GLP-1 weight loss can be lean mass — muscle. The goal is feeling stronger, not just smaller, and that means protein targets and strength work alongside the medication.
Read what the studies say
Cost Is the #1 Reason Women Quit — Plan It Like the Family Budget
Fewer than one in four patients are still on a GLP-1 after a year, and cost drives most of the drop-off. Pick a provider you can stick with — not the cheapest first month.
Read the cost storyWhy this page exists
The research on GLP-1s and women's health — hormones, cycles, perimenopause, pregnancy — is years behind the demand, and the coverage is worse. I read what exists, I say plainly what's approved versus what's promising, and I never dress up early research as settled science. When the evidence moves, this page moves with it.
See the full research rundown